Sonoma Pharmaceuticals (NASDAQ: SNOA)
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-14 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | ||||||
REV | 3.983M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Sonoma Pharmaceuticals (NASDAQ: SNOA) through any online brokerage.
Other companies in Sonoma Pharmaceuticals’s space includes: Cingulate (NASDAQ:CING), Dermata Therapeutics (NASDAQ:DRMA), Baudax Bio (NASDAQ:BXRX), Pulmatrix (NASDAQ:PULM) and Aytu BioPharma (NASDAQ:AYTU).
The latest price target for Sonoma Pharmaceuticals (NASDAQ: SNOA) was reported by Benchmark on Friday, July 20, 2018. The analyst firm set a price target for 3.00 expecting SNOA to fall to within 12 months (a possible -0.33% downside). 0 analyst firms have reported ratings in the last year.
The stock price for Sonoma Pharmaceuticals (NASDAQ: SNOA) is $3.01 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Sonoma Pharmaceuticals.
Sonoma Pharmaceuticals’s Q2 earnings are confirmed for Monday, November 14, 2022.
There is no upcoming split for Sonoma Pharmaceuticals.
Sonoma Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.